line

Press releases 2011

  • 12/16/2011
    Ad-hoc: European Commission authorizes EU-wide marketing and distribution of Biofrontera‘s Ameluz®

  • 12/7/2011
    Ad-hoc: Biofrontera AG emits new partial debentures of its 5% option bond 2011/2016

  • 12/7/2011
    Ad-hoc: Biofrontera AG emits new partial debentures of its 5% option bond 2011/2016

  • 11/16/2011
    Ad-hoc: Further subscription and exchange offer regarding 5% option bond 2011/2016

  • 11/11/2011
    Biofrontera invites to a 2nd shareholder evening on December 1st at 7 p.m.

  • 10/21/2011
    Ad-hoc: The EMA recommends approval of Biofrontera‘s BF-200 ALA

  • 9/22/2011
    Biofrontera delivers final documents for processing the last open issues in the drug application of BF-200 ALA

  • 8/30/2011
    Biofrontera AG – shares for investment in kind agreement registered

  • 7/21/2011
    Ad-hoc: Biofrontera AG emits 5% option bond 2011/2016

  • 7/14/2011
    Biofrontera AG extends offer to exchange its convertible bond

  • 6/16/2011
    Biofrontera agrees with ASAT on the settlement of purchase price payments with new shares

  • 6/15/2011
    Ad-hoc: Biofrontera AG – investment in kind agreement

  • 6/7/2011
    Ad-hoc: Biofrontera AG issues 5% convertible bond 2011/2016

  • 5/31/2011
    Biofrontera enforces arrangements for the market launch of BF-200 ALA

  • 3/31/2011
    Biofrontera publishes financial report 2010

  • 2/22/2011
    Ad-hoc: Biofrontera AG – 880,000 shares subscribed in capital increase

  • 1/27/2011
    Positive review of the European Medicines Agency in the approval process of BF-200 ALA

line2